BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.45, Yahoo Finance reports.
BriaCell Therapeutics Stock Down 0.9 %
BCTX stock traded down $0.01 during trading on Wednesday, reaching $0.83. The stock had a trading volume of 117,672 shares, compared to its average volume of 1,634,797. The company’s 50 day moving average is $0.80 and its two-hundred day moving average is $1.15. The company has a market capitalization of $15.09 million, a price-to-earnings ratio of -0.65 and a beta of 1.34. BriaCell Therapeutics has a one year low of $0.46 and a one year high of $5.97.
Analysts Set New Price Targets
Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of BriaCell Therapeutics in a research note on Thursday, October 3rd.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
See Also
- Five stocks we like better than BriaCell Therapeutics
- 3 REITs to Buy and Hold for the Long Term
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- What is a Secondary Public Offering? What Investors Need to Know
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- The 3 Best Fintech Stocks to Buy Now
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
